Role of gene sequencing in classifying struma ovarii: <i>BRAF</i> p.<scp>G469A</scp> mutation and <i>TERT</i> promoter alterations favour malignant struma ovarii

Abstract

Our results highlight the clinical utility of molecular sequencing in SO, based on this limited number of cases. However, as malignant SO evolve slowly, more extensive molecular studies in SO with more than 10 years' follow-up are required to draw any conclusions on the prognostic value of the associated gene alterations.